Polyak M M, Arrington B O, Stubenbord W T, Kapur S, Kinkhabwala M
Division of Transplantation, The New York Presbyterian Hospital-Cornell Medical Center, New York, New York, 10021, USA.
J Surg Res. 1999 Jul;85(1):17-25. doi: 10.1006/jsre.1999.5652.
Unlike simple cold storage, machine preservation allows dynamic assessment and manipulation of the donor organ prior to transplantation. We prospectively compared the effects of five pharmacological agents added to the perfusate during machine preservation of expanded criteria donor (ECD) kidneys in order to (1) describe their influence on perfusion parameters and (2) determine their influence on early graft outcome.
Two hundred seventy-five consecutive ECD kidneys were preserved in our laboratory between 1/1/94 and 12/31/97 by either machine perfusion (MP) or cold storage (CS). ECD kidneys were defined as those requiring pretransplant biopsy. ECD kidneys were divided by method of preservation and MP kidneys were randomized to receive prostaglandin E1 (MP+PGE1), trifluoperazine (TFP), verapamil (VER), papaverine (PAP), mannitol (MAN), or no intervention during the period of machine perfusion. CS kidneys were randomized to receive PGE1 (CS+PGE1), TFP, VER, PAP, or no intervention. All MP kidneys were preserved by continuous hypothermic pulsatile perfusion using Belzer II solution and perfusion parameters were measured every hour during pulsatile perfusion. All CS kidneys were stored in 1.0 L of University of Wisconsin (UW) solution.
The addition of PGE1 to machine perfusate increased renal flow and decreased renal resistance. Moreover, the MP+PGE1-treated group was associated with improved early graft function compared to all other groups. The addition of VER, TFP, PAP, or MAN influenced neither the perfusion characteristics nor the incidence of early graft function in MP kidneys. Similarly, the addition of VER, TFP, or PAP did not influence early graft function in the CS kidneys. The CS+PGE1 group exhibited a significantly lower incidence of early graft function than did the MP+PGE1 group.
PGE1 treatment during machine preservation improves hydrostatic perfusion parameters and reduces the incidence of delayed graft function in ECD kidneys. Moreover, the addition of PGE1, TFP, VER, or PAP to UW does not influence early graft function in the CS kidney.
与单纯冷藏不同,机器保存可在移植前对供体器官进行动态评估和处理。我们前瞻性地比较了在扩大标准供体(ECD)肾脏的机器保存过程中添加到灌注液中的五种药物制剂的效果,以便(1)描述它们对灌注参数的影响,以及(2)确定它们对早期移植结果的影响。
1994年1月1日至1997年12月31日期间,我们实验室连续对275个ECD肾脏采用机器灌注(MP)或冷藏(CS)进行保存。ECD肾脏定义为那些需要移植前活检的肾脏。根据保存方法对ECD肾脏进行分组,MP组肾脏在机器灌注期间随机接受前列腺素E1(MP+PGE1)、三氟拉嗪(TFP)、维拉帕米(VER)、罂粟碱(PAP)、甘露醇(MAN),或不进行干预。CS组肾脏随机接受PGE1(CS+PGE1)、TFP、VER、PAP,或不进行干预。所有MP组肾脏均采用Belzer II溶液进行持续低温脉动灌注保存,在脉动灌注期间每小时测量灌注参数。所有CS组肾脏均保存在1.0 L威斯康星大学(UW)溶液中。
在机器灌注液中添加PGE1可增加肾血流量并降低肾阻力。此外,与所有其他组相比,MP+PGE1治疗组的早期移植功能得到改善。添加VER、TFP、PAP或MAN对MP组肾脏的灌注特征和早期移植功能发生率均无影响。同样,添加VER、TFP或PAP对CS组肾脏的早期移植功能也无影响。CS+PGE1组早期移植功能的发生率显著低于MP+PGE1组。
机器保存期间进行PGE1治疗可改善ECD肾脏的流体静力灌注参数,并降低移植功能延迟的发生率。此外,在UW溶液中添加PGE1、TFP、VER或PAP对CS组肾脏的早期移植功能无影响。